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Abstract: The aim of this article is to review the pathophysiology and clinical role of serotonin 
receptor modulators used in the treatment of irritable bowel syndrome. Serotonin is an important 
monoamine neurotransmitter that plays a key role in the initiation of peristaltic and secretory 
reﬂ  exes, and in modulation of visceral sensations. Several serotonin receptor subtypes have 
been characterized, of which 5HT3, 5HT4, and 5HT1b are the most important for GI function. 
5HT4 agonists (eg, tegaserod) potentiate peristalsis initiated by 5HT1 receptor stimulation. 
5HT4 agonists are therefore useful in constipation predominant form of IBS and in chronic 
constipation. 5HT3 antagonists (Alosetron and Cilansetron) prevent the activation of 5HT3 
receptors on extrinsic afferent neurons and can decrease the visceral pain associated with 
IBS. These agents also retard small intestinal and colonic transit, and are therefore useful in 
diarrhea-predominant IBS. Tegaserod has been demonstrated in several randomized, placebo 
controlled trials to relieve global IBS symptoms as well as individual symptoms of abdominal 
discomfort, number of bowel movements and stool consistency. Several randomized, con-
trolled trials have shown that alosetron relieves pain, improves bowel function, and provides 
global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. 
However, ischemic colitis and severe complications of constipation have been major concerns 
leading to voluntary withdrawal of Alosetron from the market followed by remarketing with a 
comprehensive risk management program.
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Introduction
Irritable bowl syndrome (IBS) is a common, often debilitating, gastrointestinal disorder 
with a worldwide prevalence rate of 10%–20% (Camilleri and Choi 1997). IBS ranks as 
the most common medical diagnosis among gastroenterologists and the seventh-leading 
diagnosis among primary care physicians in the U.S. (Sandler et al 2002). IBS is costly 
in terms of medical treatments and diagnostic procedures (Levy et al 2001), time lost 
from work (Hahn et al 1999), and nonmonetary costs such as diminished quality of 
life (Lackner et al in press) and activity limitations (Whitehead et al 1996). Each year, 
the direct (diagnostic testing, physician charges, drugs, hospital costs) and indirect 
(absenteeism, reduced work efﬁ  ciency, income loss, transportation, early retirement) 
costs of IBS in the US are pegged at $1.7–$10 billion and $19.2 billion, respectively 
(Talley et al 1995; American Gastroenterological Association 2002).
The diagnosis of IBS is based on the symptom-based classiﬁ  cation system known 
as the Rome criteria (Drossman et al 2000). To meet diagnostic criteria for IBS, 
Rome criteria require that in the preceding 12 months the patient must experience 
12 weeks (need not be consecutive) of abdominal pain or discomfort with two out of 
three features:
•  Relieved with defecation; and/or
•  Onset associated with a change in frequency of stool; and/or
•  Onset associated with a change in appearance of stool.Therapeutics and Clinical Risk Management 2008:4(1) 42
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IBS can be either diarrhea predominant (IBS-D), 
constipation predominant (IBS-C) or present with diarrhea 
alternating with constipation (IBS-A).
Therapy
The management of this disorder should be guided by he 
basic ethical principal of nonmaleﬁ  cence (ﬁ  rst, do no harm), 
the establishment of a sound physician-patient relationship, 
and the judicious use of pharmacologic agents to target the 
patient’s primary symptoms. Conventional treatments for 
irritable bowel syndrome include use of bulking agents, 
antispasmodics agents, antidiarrheal agents and tricyclic 
antidepressants. While these treatments can, for some patients, 
be effective for isolated symptoms, they have a disappointing 
track record for the full range of symptoms of IBS. This has 
fuelled intense research to develop newer medications for the 
treatment of this common disorder. The most exciting devel-
opments have been related to understanding the functioning 
of the enteric nervous system at the molecular level. Better 
understanding of the role of serotonin and serotonin receptors 
in intestinal motility as well as in gut-brain signaling has lead 
to development of newer drugs that that have been studied 
in several randomized controlled trials. These serotonergic 
agents have been demonstrated to have statistically signiﬁ  cant 
but modest efﬁ  cacy in patients with irritable bowel syndrome. 
There is hope that further research in this ﬁ  eld will lead to 
development of medications that will be safe and effective, 
and will target speciﬁ  c disturbances in intestinal motility and 
visceral hypersensitivity at the molecular level.
Enteric nervous system, serotonin 
and serotonin receptors
Serotonin is a monoamine neurotransmitter of profound 
importance in the enteric nervous system. About 95% of 
the serotonin in the body is found in the GI tract; 90% is 
in enterochromafﬁ  n cells (EC cells) and the remaining 
10% in enteric neurons. It plays a key role in the initiation 
of peristaltic and secretory reﬂ  exes (Grider et al 96), and 
in modulation of visceral sensations (Kilkens et al 2004). 
There are more than 25 receptor subtypes; 5HT3, 5HT4, and 
5HT1b are most important for GI function. In the central 
nervous system, the highest levels of 5-HT3 receptor are in 
the brainstem, particularly in the nucleus tractus solitarius, 
area postrema, and dorsal motor nucleus of the vagus nerve 
(Gershon 2004; Baker 2005).
The function of the ENS is coordinated by the central 
nervous system. Parasympathetic efferent pathways consist 
of the vagus and sacral nerves. They exert an excitatory effect 
on the enteric neurons. The sympathetic efferent ﬁ  bers inhibit 
GI activity. Sensory information is transmitted to the CNS via 
the vagus and splanchnic afferents. The splanchnic afferent 
neurons transmit pain sensation, whereas the parasympathetic 
afferent ﬁ  bers transmit physiological information and non-
noxious sensation (Goyal and Hirano 1996; Baker 2005). The 
enteric nervous system is composed of two major intercon-
nected plexuses of ganglia and nerve processes; the myenteric 
plexus and the submucous plexus. The myenteric plexus is 
located between the longitudinal and circular muscle layers 
whereas the submucous plexus is located in the submucosa 
between the muscularis mucosa and circular muscle layer 
(Goyal and Hirano 1996; Talley 2001; Baker 2005; Gershon 
2005). Intrinsic primary afferent neurons (IPANs) have cell 
bodies in the myenteric plexus (myenteric IPANs) or in the 
submocus plexus (submucous IPANs) and processes extend-
ing to muscularis mucosa as well as processes synapsing with 
interneurons. IPANs are the primary sensors and regulators of 
the ENS. Interneurons involved in motor reﬂ  exes are either 
directed cephalad or caudally and are called ascending and 
descending interneurons respectively. Interneurons synapse 
with motor neurons that are either excitatory or inhibitory 
(Goyal and Hirano 1996; Gershon 2005). Excitatory motor 
neurons secrete Ach and Substance P whereas inhibitory 
motor neurons secrete NO, VIP, ATP and PACAP. EC cells 
are neuroendocrine cells that serve as sensory tranducers 
and transmit sensory information from the gut mucosa to 
the nerve ﬁ  bers in the lamina propria. This communication 
takes place via the secretion of serotonin by EC cells into 
the lamina propria in response to luminal stimuli (Gershon 
2005). The signal is terminated by the re-uptake of serotonin 
by the serotonin reuptake transporter (SERT) present on the 
enterocytes. Serotonin stimulates IPANs and information is 
thus transmitted from EC cells via IPANs to interneurons and 
motor or secretomotor neurons. Submucosal IPANs secrete 
acetylcholine (Ach) and calcitonin gene related peptide 
(CGRP) (Gershon 2005).
The peristaltic reﬂ  ex can be elicited by stretch of the 
circular muscle layer by a bolus of food or by mucosal stimula-
tion. Muscle stretch activates extrinsic sensory neurons with 
cell bodies in the dorsal root ganglion and axonal projections 
to the neurons of the ENS. This results in the release of CGRP 
by the enteric neurons without involvement of the EC cells 
or the release of serotonin. Mucosal stimulation by a bolus, 
on the other hand, results in the release of serotonin from 
the EC cells. Serotonin acts on the 5HT1p receptors on the 
terminals of submucosal IPANs resulting in the secretion of 
Ach and CGRP by the IPANs. 5HT4 receptors are present Therapeutics and Clinical Risk Management 2008:4(1) 43
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pre-synaptically on the distal terminals of submucosal 
IPANs. Stimulation of 5HT4 receptors by serotonin aug-
ments the release of Ach and CGRP. Both sensory pathways 
are coupled to the same effector limbs. Stimulation of 5HT4 
receptors on submucosal IPANs by serotonin augments the 
release of Ach and CGRP. The released Ach and CGRP 
excite the ascending and descending interneurons, which in 
turn release Ach at their terminals. Presynaptic 5HT4 recep-
tors also augment this Ach release (Grider 1996; Gershon 
2004, 2005). The ascending interneurons synapse with excit-
atory motor neurons cephalad to the site of stimulus (bolus), 
which release Ach and substance P. This results in smooth 
muscle contraction cephalad to the bolus. The descending 
interneurons synapse with inhibitory motor neurons caudad 
to the bolus, which release NO and VIP, resulting in smooth 
muscle relaxation. This whole process results in propagation 
of the bolus in a coordinated fashion. 5HT1p receptors play a 
key role in the initiation of peristalsis, whereas 5HT4 recep-
tors play a role in augmenting the release of neurotransmitters 
once the process is initiated by 5HT1p receptor stimulation 
(Grider 1996; Gershon 2004, 2005). 5HT3 receptors are 
found on the terminals of extrinsic afferent neurons, and are 
involved in the transmission of sensory stimuli to the CNS. 
Noxious stimuli are carried by spinal afferents while nausea, 
bloating and other non-painful sensations are transmitted by 
parasympathetic afferents. 5HT3 receptors are also present 
on myenteric IPANs and on other neurons in the myenteric 
plexus where they mediate fast excitatory neurotransmis-
sion (Gershon 2004, 2005). 5HT3 receptors do not play a 
signiﬁ  cant role in peristaltic and secretory reﬂ  exes, but potent 
antagonists can result in slowing of GI motility.
Deletion of SERT gene in mice results in diarrhea from 
excess serotonin availability, followed by constipation from 
desensitization of serotonin receptors (Chen et al 2001). The 
5HT1p agonist 5-hydroxyindalapine causes severe diarrhea 
by activating submucosal IPANs (Gershon 2005). Similarly 
5HTP-DP (N-acetyl-5-hydroxytryptophy-5-hydroxytrypto-
phan amide) an antagonist of 5HT1p blocks peristaltic and 
secretory reﬂ  exes, and can cause paralytic ileus (Gershon 
2005). The 5HT4 agonist tegaserod potentiates peristalsis ini-
tiated by 5HT1 receptor stimulation by acting on pre-synaptic 
5HT4 receptors and augmenting the release of neurotransmit-
ters (Grider 1996; Gershon 2004, 2005). 5HT4 agonists are 
therefore useful in constipation predominant form of IBS 
and in chronic constipation. 5HT4 receptors are not present 
on extrinsic afferent neurons and therefore do not directly 
modulate sensation. However, by improving bowel motil-
ity, they may improve abdominal pain. 5HT3 antagonists 
(Alosetron and Cilansetron) prevent the activation of 5HT3 
receptors on extrinsic afferent neurons and can decrease the 
visceral pain associated with IBS (Gershon 2005). They also 
decrease gastrointestinal motility, and are therefore useful 
in IBS-D.
Role of serotonin in the pathogenesis of IBS is being 
investigated. In a recent study (Atkinson et al 2005), 84 
IBS patients and 35 healthy volunteers had platelet-depleted 
plasma 5-HT/5-HIAA concentrations measured before and 
after a standard meal. D-IBS patients had raised concentra-
tions of 5-HT in their plasma probably as a consequence of 
reduced metabolism and uptake. However a 5-HT response 
to meal ingestion in these patients was demonstrated to be 
similar to healthy controls. On the other hand, c-IBS had a 
very limited 5-HT response to meal ingestion as demonstrated 
by the low concentrations of both 5-HT and 5-HIAA. These 
observations lead the authors to conclude that D- and C-IBS 
may be primarily disorders of reduced 5-HT reuptake and 
release, respectively. These are very interesting ﬁ  ndings, 
but other studies are needed to replicate and validate these 
results.
Tegaserod
Tegaserod, an aminoguanidine indole derivative of sero-
tonin, is a selective partial agonist of pre-synaptic 5HT4 
receptors on submucosal IPANs (Camilleri 2001, 2002, 
2004; Talley 2003; Chey 2004). It augments 5HT1 recep-
tor mediated release of Ach and CGRP from submucosal 
IPANs, thereby potentiating the peristaltic reﬂ  ex (Grider 
1996; Gershon 2004, 2005). Tegaserod has been demon-
strated to accelerate gastric emptying and small intestinal 
transit, and induce a small but signiﬁ  cant acceleration of 
colonic transit during acute administration (Degan et al 
2001). It accelerates orocecal transit in irritable bowel 
syndrome patients with constipation (Prather et al 2000). 
It has also been demonstrated to reduce the sensitivity to 
rectal distension in healthy subjects without altering the 
intensity of subjective pain perception or rectal compliance 
(Cofﬁ  n et al 2003).
The efﬁ  cacy and safety of tegaserod has been demon-
strated by several large randomized controlled trials. In a 
randomized, placebo-controlled, double-blind, multicenter 
study of eight hundred and eighty-one patients with irritable 
bowel syndrome, tegaserod 2 mg twice daily or 6 mg twice 
daily showed a statistically signiﬁ  cant relief of overall irri-
table bowel syndrome symptoms, measured by a weekly, 
self-administered questionnaire. There was also a statistically 
significant improvement in individual irritable bowel Therapeutics and Clinical Risk Management 2008:4(1) 44
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syndrome symptoms of abdominal discomfort/pain, number 
of bowel movements and stool consistency. Tegaserod was 
well tolerated, transient diarrhea being the only adverse event 
seen more frequently with tegaserod than placebo (Muller-
Lissner et al 2001). In another randomized, double-blind, 
multicenter study of 1519 women tegaserod 6 mg BID for 
12 weeks produced signiﬁ  cant improvements in the Subject’s 
Global Assessment of Relief compared to placebo. These 
improvements were seen within the ﬁ  rst week, and were 
maintained throughout the treatment period. However, at the 
end of the study period there was a smaller treatment differ-
ence v/s placebo due to an increase in placebo response to 
61% as compared to 67% in the treatment group. Diarrhea 
was the most frequent side effect but it lead to discontinu-
ation of tegaserod in only 1.6% of patients (Novick et al 
2002). Satisfactory relief from IBS symptoms was also 
demonstrated in a trial of 520 patients from the Asia-Paciﬁ  c 
region with IBS, excluding those with diarrhea predominant 
IBS who were randomized to receive either tegaserod 6 mg 
twice daily or placebo for a 12 week treatment period. A 
clinically relevant effect was observed as early as week 1 and 
was maintained throughout the treatment period (Kellow 
et al 2003). Similarly in an 8-week, open-label, prospec-
tive, multicenter study from Switzerland, tegaserod 6 mg 
bid was demonstrated to be safe, effective, and well toler-
ated in the treatment of patients with non-diarrhea irritable 
bowel syndrome (Fried et al 2005). In a randomized, placebo 
controlled trial from Sweden, the odds of satisfactory relief 
from irritable bowel symptoms were 54% higher over weeks 
I–4 and 78% higher over weeks 1–12 in the tegaserod (6 mg 
twice daily) group than in the placebo group. Diarrhea led 
to discontinuation in 2.8% of tegaserod patients (Nyhlin 
2004). In a meta-analysis of randomized controlled trials, 
tegaserod showed a signiﬁ  cant effect in women with an 
odds ratio of 1.4 (CI: 1.2–1.5) (Lesbros-Pantoﬂ  ickova et al 
2004). A systematic review of eight trials (IBS) showed 
relative risk (RR) of being a responder in terms of global
relief of GI symptoms was signiﬁ  cantly higher with tegaserod 
12 mg (number needed to treat of 14) and tegaserod 4 mg 
(number needed to treat of 20) compared with placebo. When 
all tegaserod doses were combined the RR of being a responder 
was 1.17 (95% CI 1.08, 1.27), with a number needed to treat 
of 17. Symptoms indicative of GI motility such as number 
of bowel movements and days without bowel movements 
were improved consistently. Tegaserod did not signiﬁ  cantly 
improve abdominal pain and discomfort. (Evans et al 2004). 
In a randomized trial (Kkoshoo et al 2006), 48 patients with 
constipation predominant irritable bowel syndrome were 
allocated to treatment with a laxative alone (polyethylene 
glycol 3350 oral solution) or combination therapy with the 
laxative and tegaserod. Treatment with the laxative alone 
resulted in signiﬁ  cant increase in frequency of bowel move-
ments but not signiﬁ  cant improvement in pain. The combi-
nation therapy led to signiﬁ  cant increase in the frequency 
of bowel movements and also signiﬁ  cant reduction in pain. 
Re-treatment with tegaserod for recurrence of symptoms after 
an eight week withdrawal period has been demonstrated to be 
as efﬁ  cacious and safe as the initial treatment (Muller-Lissner 
et al 2005). Tegaserod has been shown to signiﬁ  cantly reduce 
work productivity loss by 2.5 hours per week, calculated 
on the basis of a 40 hour work week (Reilly et al 2005). In 
a model based on economic and epidemiologic published 
literature and clinical trial results, medical therapy for IBS 
with tegaserod was predicted to be cost-effective from an 
employer’s perspective for the treatment of women with 
IBS-C (Smith et al 2005).
Tegaserod may also be useful in conditions other than 
IBS, like chronic constipation and non-ulcer dyspepsia. In a 
randomized trial of 1264 patients with chronic constipation 
there was a signiﬁ  cant increase in complete spontaneous 
bowel movements per week in patients receiving tegaserod. 
The number needed to treat was 7.3 for the 6 mg twice daily 
dose compared with 11.1 for tegaserod 2 mg twice daily. 
Signiﬁ  cant improvements were also seen in stool form and in 
global assessment of bowel habits and constipation. The most 
common adverse events, headache and abdominal pain, were 
more frequent with placebo than with tegaserod (Johanson 
2004; Kamm et al 2005). However, head to head comparison 
with more conventional laxatives is needed before its use can 
be justiﬁ  ed for this indication. Tegaserod may a have a role 
in the management of some patients with non ulcer dyspepsia 
(Cremonini et al 2004). Tegaserod has been demonstrated to 
accelerate the return of gastric function in intensive care unit 
patients with gastroparesis in case reports (Bank et al 2005). 
The most common adverse effect is diarrhea. In randomized 
controlled trials diarrhea was reported by 8.8% of patients 
treated with tegaserod versus 3.8% of patients receiving 
placebo (Schoenfeld 2004).
As far as the safety is concerned, no cases of isch-
emic colitis were reported among 7000 patients randomly 
assigned to receive tegaserod in placebo-controlled trials of 
at least three months’ duration. However, between August 
2002 and March 2004, the FDA received 20 reports of 
cases of ischemic colitis associated with the use of tegas-
erod. As a result of these reports, the labeling of tegaserod 
(Zelnorm) was updated to alert the prescribers of the risk of Therapeutics and Clinical Risk Management 2008:4(1) 45
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tegaserod-associated ischemic colitis (Brinker et al 2004; 
DiBaise 2005). Higher cholecystectomy rates have been 
noted among tegaserod treated but no causal relationship 
has been established. Higher rates of cholecystectomy, 
appendectomy and hysterectomy have also been reported 
in IBS patients in general unrelated to any medication use. 
Gallbladder contractility variables were similar after 2 wk 
of treatment with tegaserod 6 mg twice daily and placebo 
in healthy female subjects and female patients with IBS-C. 
There were no signiﬁ  cant changes in the luminal diameters 
of the common hepatic duct or common bile duct after tega-
serod compared to placebo, and no signiﬁ  cant ductal dilation 
was observed during maximal gallbladder emptying (Fisher 
et al 1999). Tegaserod-treated patients in RCTs have not 
demonstrated signiﬁ  cant prolongation of the QTc interval or 
cardiac arrhythmias compared with placebo-treated patients. 
Supra-therapeutic doses in healthy volunteers did not affect 
electrocardiographic parameters (Morganroth et al 2002). 
No clinically signiﬁ  cant adverse drug-drug interactions have 
been reported. Manufacturer listed contraindications include 
severe renal impairment, moderate or severe hepatic impair-
ment, history of bowel obstruction, symptomatic gallbladder 
disease, suspected sphincter of Oddi dysfunction, or abdomi-
nal adhesions. Treatment should not be started in patients 
with diarrhea or in those who experience diarrhea frequently. 
Pregnancy category is B, and it not recommended during 
lactation. In February and March 2007, FDA reviewed the 
data of 29 studies that included 11,614 patients treated with 
tegaserod and 7,031 treated with placebo. The patients treated 
with tegaserod had a higher chance of having a myocardial 
infarction, stroke or angina than those who were treated with 
placebo (0.1% vs 0.01%).  A public health advisory was 
released by FDA in March 2007, and tegaserod was taken 
off the market by Novartis. In July 2007, FDA announced 
that it is permitting restricted use of tegaserod under an 
investigational new drug (IND) protocol to treat IBS-C and 
chronic idiopathic constipation in women younger than 55 
who meet speciﬁ  c guidelines.
Alosetron
5HT3 receptors are present on the intrinsic neurons within the 
myenteric plexus and play a minor role in the ENS neurotrans-
mission. Being a potent 5HT3 antagonist, alosetron can slow 
intestinal motility. More importantly, 5HT3 receptors are 
present on the extrinsic sensory neurons and vagal afferents 
involved in the transmission of noxious and non-noxious (eg, 
nausea, bloating) sensations respectively. A 5HT3 antagonist 
can be expected to inhibit these sensations (Gershon 2005). 
Alosetron signiﬁ  cantly retards small intestinal (Veramontes 
et al 2001) and colonic (Houghton et al 2000; Veramontes 
et al 2001) transit in diarrhea-predominant IBS patients; 
this effect is more prominent in females (Veramontes et al 
2001). Alosetron has been demonstrated, on isobaric phasic 
distension studies, to increases the compliance of the colon 
to distension. This was postulated to contribute to changes 
in perception of colonic distension (Delvaux et al 1998). 
Alosetron increases the number and propagation length of 
high amplitude colonic contractions which results in a para-
doxical decrease in stool frequency (Clemens et al 2002). 
Noxious intestinal stimuli like colorectal distension elicit 
a drop in the blood pressure in rats. This reﬂ  ex depressor 
response can be used as a measure of visceral nociception. 
Alosetron has been shown to inhibit this vasodepressor 
response to colorectal distension by blocking the 5HT3 
receptors (Kozlowski et al 2000). In functional brain imaging 
studies, alosetron has been shown to decrease brain activity in 
bilateral frontotemporal cortex and various limbic structures 
in response to colorectal distension (Mayer et al 2002).
Several multicenter, randomized, placebo controlled trials 
(Lembo et al 1996; Jones et al 1999; Camilleri et al 2000, 
2001; Watson et al 2001; Wolfe at al 2001) have shown that 
alosetron relieves pain, improves bowel function, controls 
bowel urgency, provides global symptom improvement and 
improves quality of life in women with diarrhea-predominant 
irritable bowel syndrome. In a randomized controlled trial of 
714 patients (Chey et al 2004) alosetron-treated patients had 
signiﬁ  cantly greater 48-wk average adequate relief (p = 0.01) 
and urgency control (p   0.001) rates compared with pla-
cebo. Adverse events were similar between treatment groups, 
except for constipation. Neither ischemic colitis nor serious 
events related to bowel motor dysfunction was reported.
In a meta-analysis of six high quality randomized 
controlled trials (Cremonini et al 2003) the odds ratio for 
adequate relief of pain or global symptoms improvement 
with alosetron 1 mg twice a day was 1.81 (95% conﬁ  dence 
interval 1.57–2.10). The number needed to treat to achieve 
improvement in one patient over placebo was seven. 93% of 
the patients were females, and 75% had diarrhea predomi-
nant IBS. In another meta-analysis of randomized controlled 
trials (Lesbros-Pantoﬂ  ickova et al 2004) alosetron was 
found to be effective in treatment of women with diarrhea 
predominant IBS with OR of 2.2 (95% CI: 1.9–2.6).
Safety issues have overshadowed the reputation of alos-
etron. 18 cases of ischemic colitis and 11 cases of serious 
complications of constipation were reported out of 11,874 
patients taking alosetron during alosetron’s clinical trials’ Therapeutics and Clinical Risk Management 2008:4(1) 46
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experience. During post marketing surveillance, the Food and 
Drug Administration received reports of 84 cases of ischemic 
colitis (including two deaths) and 113 cases of serious com-
plications of constipation (including two deaths) associated 
with the use of alosetron from March 2000 to March 2002 
(Avigan et al 2003). GlaxoSmithKline voluntarily withdrew 
it from the market in November, 2000. In June 2002, the FDA 
approved the remarketing of alosetron with a comprehensive 
risk management program. In this program, the prescribers 
attest to their knowledge and abilities in managing IBS and to 
their knowledge of the potential complications of alosetron. 
In addition, the prescribers agree to educating the patients 
about alosetron’s risks and beneﬁ  ts and reporting serious 
adverse events to GSK and the FDA. The drug is indicated 
only in women with severe diarrhea-predominant IBS who 
have chronic IBS symptoms, who experience failure of the 
usual therapies for IBS, and who have had other GI diseases 
ruled out. Another recommendation was to start at a reduced 
dose of 1 mg once daily, which can be increased to 1 mg 
twice daily after four weeks if the lower dose is well-tolerated 
but the symptoms are not adequately controlled. 37 serious 
adverse events have been reported since alosetron was rein-
troduced to the market (Traynor 2004), including 6 cases of 
ischemic colitis. No deaths attributable to alosetron have been 
reported since its reintroduction into the market. Alosetron 
is contraindicated in patients with constipation. However no 
risk factors have been identiﬁ  ed that can predict the develop-
ment of ischemic colitis in alosetron treated patients.
Newer agents
A number of newer serotonin receptor modulators are being 
developed in an attempt to reduce the side effects while 
maintaining efﬁ  cacy. These include renzapride, cilansetron, 
and ramosetron among others. Renzapride is a benzamide 
derivative with combined 5-HT3-receptor antagonist and 
5-HT4-receptor agonist activity. In a dose-ranging phar-
macodynamic study, it caused clinically signiﬁ  cant dose-
related acceleration of colonic transit. This acceleration of 
transit was associated with improvement of bowel function 
in female IBS-C patients (Camilleri et al 2004). Phase III 
clinical trials are currently underway. Cilansetron is another 
5-HT3 antagonist that has been investigated for treatment of 
diarrhea-predominant IBS. It reduces diarrhea and pain but 
there have been reports of severe constipation and ischemic 
colitis (Bradette et al 2004; Coremans et al 2004). It did not 
received FDA approval because of these concerns. Ramose-
tron, a 5-HT3-receptor antagonist with antiemetic properties, 
is being investigated in phase II trials in Japan for treatment 
of diarrhea predominant IBS. Newer partial agonists of the 
5-HT3 receptor like ME3412 (5-chloro-2-(1,4-diazacyclohep-
tan-1-yl)-7-methylbenzoxazole), may relieve diarrhea with 
low risk of inducing constipation (Kawano et al 2005).
Selective serotonin reuptake 
inhibitors
SSRIs are typically used in IBS patients as antidepressants, 
especially in patients with co-existing depressive disorder, 
anxiety disorder, panic disorder, or phobias. Any potential 
effects on serotonergic neurotransmission at the level of 
enteric nervous system have not been well studied. Fluoxetine 
has been shown to decrease orocecal and whole gut transit 
times in both constipation-predominant IBS patients and 
controls (Gorard et al 1994). In another study (Kuiken et al 
2003) forty non-depressed IBS patients underwent a rectal 
barostat study to assess the sensitivity to rectal distention 
before and after 6 weeks of treatment with ﬂ  uoxetine 20 mg 
or placebo. At baseline, 21 of 40 patients showed hypersen-
sitivity to rectal distention. Fluoxetine did not signiﬁ  cantly 
alter the threshold for discomfort/pain relative to placebo, 
either in hypersensitive or in normosensitive IBS patients. 
Overall there was no signiﬁ  cant difference in abdominal 
pain scores at six weeks, but in the subgroup of hypersensi-
tive patients, ﬂ  uoxetine signiﬁ  cantly reduced the number of 
patients reporting abdominal pain.
In a study of forty-four cases of irritable bowel syndrome 
with predominance of pain and constipation (Vahedi et al 
2005), ﬂ  uoxetine was signiﬁ  cantly more effective than pla-
cebo in decreasing abdominal discomfort, relieving feeling 
of bloating, increasing frequency of bowel movements and 
decreasing consistency of stool. Mean number of symptoms 
per patient decreased from 4.6 to 0.7 in the ﬂ  uoxetine group 
vs. 4.5 to 2.9 in controls (p   0.001). In a trial of paroxitine 
versus placebo among patients already on a high ﬁ  ber diet 
(Tabas et al 2004; Talley 2004), overall well-being improved 
more with paroxetine than with placebo (63.3% vs 26.3%; 
p = 0.01), but abdominal pain, bloating, and social function-
ing did not. This improvement in well being held true for 
non-depressed IBS patients as well. For patients with severe 
IBS, both psychotherapy and paroxetine have been shown 
to improve health-related quality of life at no additional 
cost (Creed et al 2003). More recently, Tack et al (2006) 
found that the SSRI citalapram improved the severity of 
IBS symptoms including pain in a placebo-controlled study 
of 23 non-depressed IBS patients. Changes in pain were 
independent of changes in anxiety or depression, suggesting 
that SSRI may have peripheral beneﬁ  ts. While promising, Therapeutics and Clinical Risk Management 2008:4(1) 47
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enthusiasm is tempered by the sample size was small and the 
lack of signiﬁ  cant impact on stool pattern.
Conclusion
Serotonin plays a key role in the initiation of peristaltic and 
secretory reﬂ  exes, and in modulation of visceral sensations. 
5HT4 agonists (eg, tegaserod) potentiate peristalsis initiated 
by 5HT1 receptor stimulation by acting on pre-synaptic 5HT4 
receptors and augmenting the release of neurotransmitters. 
5HT4 agonists are therefore useful in constipation predominant 
form of IBS and in chronic constipation. 5HT3 antagonists 
(Alosetron and Cilansetron) prevent the activation of 5HT3 
receptors on extrinsic afferent neurons and can decrease the 
visceral pain associated with IBS. They decrease gastrointes-
tinal motility, and are therefore useful in IBS-D. Serotonin 
receptor modulators are an area of active research, and there 
is hope that newer agents will be developed, that are more 
effective and better tolerated.
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